Profil bibliographique

Janet Hammond

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

66Publications signalées

2697Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Nosocomial Infections in ICUHepatitis C virus researchRespiratory viral infections researchHIV/AIDS drug development and treatmentPneumonia and Respiratory Infections

Publications récentes

Accès ouvert 2025 articleOpenAlex

Safety, Pharmacokinetics, and Activity of AT-752, a Novel Nucleotide Prodrug with Pan-Serotype Activity against Dengue Virus: A Phase 2, Randomized, Double-Blind Study

Arantxa Horga, Mauro Martins Teixeira, Swapnav Borthakur, Shannan Lynch et autres

8 citationsAmerican Journal of Tropical Medicine and Hygiene

2025 conference-abstractOpenAlex

WED-280 Pharmacokinetics of bemnifosbuvir in participants with renal impairment

Xiao-Jian Zhou, Gaetano Morelli, Jean‐Philippe Lafrance, Maureen Montrond et autres

1 citationJournal of Hepatology

2025 conference-abstractOpenAlex

TOP-251 Efficacy and safety of Bemnifosbuvir and Ruzasvir after 8 weeks of treatment in patients with chronic hepatitis C virus (HCV) infection

Alina Jucov, Saeed Hamid, Laura Iliescu, Elena Ermacicova et autres

5 citationsJournal of Hepatology

2025 conference-abstractOpenAlex

WED-278 Pharmacokinetics of bemnifosbuvir in participants with hepatic impairment

Xiao‐Jian Zhou, Thomas Marbury, Juan Rondon, William B. Smith et autres

0 citationsJournal of Hepatology

2025 conference-abstractOpenAlex

WED-279 No DDI between Bemnifosbuvir/Ruzasvir and Bictegravir/ Emtricitabine/Tenofovir Alafenamide

Xiaojian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch et autres

0 citationsJournal of Hepatology

Accès ouvert 2025 articleOpenAlex

Clinical Evaluation of Potential Interaction Between Bemnifosbuvir and Ruzasvir With an Assessment of Food Effect: Results of a Phase 1 Study in Healthy Participants

Xiao‐Jian Zhou, Gaetano Morelli, Maureen Montrond, Shannan Lynch et autres

4 citationsClinical Pharmacology in Drug Development

2024 conference-abstractOpenAlex

THU-382 Lead-in cohort results from a phase 2 study of a novel 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection

Alina Jucov, Brian E. Conway, Laura Iliescu, Paul Mitruț et autres

3 citationsJournal of Hepatology

Accès ouvert 2024 articleOpenAlex

Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19

Xiao-Jian Zhou, Arantxa Horga, Adeep Puri, Lee C. Winchester et autres

4 citationsJournal of Antimicrobial Chemotherapy

Accès ouvert 2024 articleOpenAlex

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus

Xiao-Jian Zhou, Jason D. Lickliter, Maureen Montrond, Laura Ishak et autres

13 citationsAntimicrobial Agents and Chemotherapy

Accès ouvert 2024 preprintOpenAlex

Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19

Xiao‐Jian Zhou, Arantxa Horga, Adeep Puri, Lee C. Winchester et autres

0 citationsmedRxiv

Accès ouvert 2024 preprintOpenAlex

First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus

Xiaojian Zhou, Jason D. Lickliter, Maureen Montrond, Laura Ishak et autres

1 citationmedRxiv

Accès ouvert 2024 articleOpenAlex

Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase

Xiao-Jian Zhou, Steven S. Good, Keith Pietropaolo, Qi Huang et autres

10 citationsExpert Opinion on Investigational Drugs

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.